Lexeo Therapeutics, Inc. Common Stock
General ticker "LXEO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $189.0M (TTM average)
Lexeo Therapeutics, Inc. Common Stock follows the US Stock Market performance with the rate: 51.6%.
Estimated limits based on current volatility of 3.1%: low 9.35$, high 9.94$
Factors to consider:
- Total employees count: 58 as of 2023
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.21$, 9.56$]
- 2025-12-31 to 2026-12-31 estimated range: [2.61$, 7.59$]
Short-term LXEO quotes
Long-term LXEO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.65MM | $0.00MM | $0.00MM |
| Operating Expenses | $61.16MM | $68.51MM | $105.77MM |
| Operating Income | $-60.51MM | $-68.51MM | $-105.77MM |
| Non-Operating Income | $1.23MM | $2.12MM | $7.43MM |
| Interest Expense | $0.09MM | $0.20MM | $0.11MM |
| R&D Expense | $49.16MM | $53.13MM | $74.09MM |
| Income(Loss) | $-59.28MM | $-66.39MM | $-98.33MM |
| Profit(Loss)* | $-59.28MM | $-66.39MM | $-98.33MM |
| Stockholders Equity | $-112.95MM | $113.53MM | $116.84MM |
| Assets | $97.08MM | $139.81MM | $146.94MM |
| Operating Cash Flow | $-54.56MM | $-59.50MM | $-81.15MM |
| Capital expenditure | $0.90MM | $0.17MM | $0.48MM |
| Investing Cash Flow | $-0.90MM | $-0.17MM | $-94.08MM |
| Financing Cash Flow | $0.19MM | $103.79MM | $88.78MM |
| Earnings Per Share** | $-2.36 | $-2.49 | $-3.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.